World News
Chemotherapy-Free Triplet 'Sets a New Benchmark' in Follicular Lymphoma

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — ORLANDO — Adding the bispecific antibody epcoritamab (Epkinly) to a standard chemotherapy-free regimen for relapsed or refractory follicular lymphoma improved responses and reduced the risk of disease progression or death…


:max_bytes(150000):strip_icc()/Health-GettyImages-1154467927-df3a23535a2d4fd5a79549fbf521c037.jpg?w=390&resize=390,220&ssl=1)
